Preoperative plasma fibrinogen levels predict mortality after coronary artery bypass grafting

Henry Völzke; Daniel M. Robinson; Volker Kleine; Sabine Hertwig; Christian Schwahn; Rita Grimm; Lothar Eckel; Rainer Rettig

doi:10.1055/s-0037-1613476

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2003; 89(05): 885-891
DOI: 10.1055/s-0037-1613476

Vascular Development and Vessel Remodelling

Schattauer GmbH

Preoperative plasma fibrinogen levels predict mortality after coronary artery bypass grafting

Henry Völzke

¹Department of Epidemiology and Social Medicine

,

Daniel M. Robinson

²Clinic of Internal Medicine B

,

Volker Kleine

²Clinic of Internal Medicine B

,

Sabine Hertwig

²Clinic of Internal Medicine B

,

Christian Schwahn

³Department of Biostatistics and, Ernst Moritz Arndt University, Greifswald, Germany

,

Rita Grimm

⁴Department of Physiology, Ernst Moritz Arndt University, Greifswald, Germany

,

Lothar Eckel

⁵Heart Center Mecklenburg-Vorpommern, Karlsburg, Germany

,

Rainer Rettig

⁴Department of Physiology, Ernst Moritz Arndt University, Greifswald, Germany

› Institutsangaben

Abstract

als PDF herunterladen

Summary

This study was designed to investigate whether plasma fibrinogen levels as well as the β-fibrinogen –455 G/A genotype are associated with outcome after coronary artery bypass graft (CABG) operation.

We enrolled 249 consecutive CAD patients one day before they underwent a CABG operation. Data from 220 patients with available plasma fibrinogen levels were analyzed. The primary end-point was total mortality, the secondary end-point mortality from cardiac causes or the need for myocardial revascularization. The 2-year total mortality was 9.1% in the entire cohort. Multivariable analysis revealed an independent relationship between the primary end-point and preoperative plasma fibrinogen levels but not the β-fibrinogen –455 G/A geno-type. Neither preoperative plasma fibrinogen levels nor the β-fibrinogen –455 G/A genotype could predict the secondary end-point.

We conclude, that elevated preoperative plasma fibrinogen levels, but not the β-fibrinogen -455 G/A genotype predict the total mortality after CABG operation.

Keywords

Fibrinogen - β-fibrinogen-455 G/A gene polymorphism - coronary artery disease - coronary artery bypass graft operation

PDF (232 kb)

Referenzen

References
1 Moor E, Hamsten A, Blombäck M, Herzfeld I, Wiman B, Ryden L.. Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion. Thromb Haemost 1994; 72: 335-42.
2 Cotton JM, Webb KE, Mathur A, Martin JF, Humphries SE.. Impact of the –455G->A promoter polymorphism in the β fibrinogen gene on stimulated fibrinogen production following bypass surgery. Thromb Haemost 2000; 84: 926-7.
3 Efthimiadis A, Lefkos N, Psirropoulos D, Papadopoulos I, Boudonas G, Lefkou E, Efthimiadis I, Tsapas G.. Risk factors of ischaemic heart disease and long-term outcome after coronary bypass surgery. J Cardiovasc Surg 2001; 42: 731-4.
4 Wilhelmsen L, Svärdsudd K, KorsanBengsten K, Larsson B, Wekin L, Tibblin G.. Fibrinogen as a risk factor for stroke and myocardial infarction. New Engl J Med 1984; 258: 501-5.
5 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG.. Haemostatic function and ischaemic heart disease: Principle results of the Northwick Park Heart Study. Lancet 1986; II: 533-7.
6 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB.. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258: 1183-6.
7 Rosengreen A, Wilhelmsen L.. Fibrinogen, coronary heart disease and mortality from all causes in smokers and nonsmokers. The study of men born in 1933. J Internal Med 1996; 239: 499-507.
8 Rallidis LS, Papageorgakis NH, Megalou AA, Anagnostou ED, Chatzidimitriou GI, Tsitouris GK.. Fibrinogen in the offspring of men with premature coronary artery disease. Eur Heart J 1995; 16: 1814-8.
9 Thomas AE, Green FR, Lamlum H, Humphries SE.. The association of combined α and β fibrinogen genotype on plasma fibrinogen levels in smokers and non-smokers. J Med Genet 1995; 32: 585-9.
10 Thomas AE, Green FR, Humphries SE.. Association of genetic variation at the β-fibrinogen gene locus and plasma fibrinogen levels; interaction between allele frequency of the G/A^-455 polymorphism, age and smoking. Clin Genet 1996; 50: 184-90.
11 Henschen A, Lottspeich F, Kehl M, Southan C.. Covalent structure of fibrinogen. Ann NY Acad Sci 1983; 408: 13-27.
12 Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE.. Variation in the promoter region of the beta fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-90.
13 Scarabin P-Y, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F.. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocar-dial infarction. The ECTIM study. Arterioscler Thromb 1993; 13: 886-91.
14 Green F, Hamsten A, Blombäck M, Humphries S.. The role of β-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-20.
15 Carter AM, Mansfield MW, Stickland MH, Grant PJ.. β-fibrinogen gene –455G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care 1996; 19: 1265-8.
16 Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou JP, Scarabin P-Y, Bara L, Green F, Cambien F.. β fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Circulation 1996; 93: 440-9.
17 de Maat MPM, Kastelein JJP, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, Bruschke AVG, Kluft C.. on the behalf of the REGRESS group. -455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men Proposed role for an acute-phase reaction pattern of fibrinogen. Arterioscler Thromb Vasc Biol 1998; 18: 265-71.
18 Kessler C, Spitzer C, Stauske D, Mende S, Stadlmüller J, Walther R, Rettig R.. The apolipoprotein E and the β-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large vessel disease. Arterioscler Thromb Vasc Biol 1997; 17: 2880-4.
19 Wang XL, Wang J, McCredie RM, Wilcken DEL.. Polymorphisms of factor V, factor VII and fibrinogen genes. Relevance to severity of coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 246-51.
20 Völzke H, Engel J, Kleine V, Schwahn C, Dahm JB, Eckel L, Rettig R.. Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery. Chest 2002; 122: 31-6.
21 Clauss A.. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat 1957; 17: 237-46.
22 Cheshire NJ, Wolfe JH, Barradas MA, Chambler AW, Mikhailidis DP.. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg 1996; 11: 479-86.
23 Risum O, Nitter-Hauge S, Abdelnoor M, Levorstad K, Arafa O, Svennevig JL.. Mortality and morbidity after coronary artery bypass surgery related to pre-operative left ventricular ejection fraction. Eur Heart J 1996; 17: 874-9.
24 Brandrup-Wognsen G, Haglid M, Karlsson T, Berggren H, Herlitz J.. Mortality during the two years after coronary artery bypass grafting in relation to perioperative factors and urgency of operation. Eur J Cardiothorac Surg 1995; 9: 685-91.
25 Thourani VH, Weintraub WS, Stein B, Geb-hart SSP, Craver JM, Jones EL, Guyton RA.. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999; 67: 1045-52.
26 Gardemann A, Schwartz O, Haberbosch W, Katz N, Weiss T, Tillmanns H, Hehrlein FW, Waas W, Eberbach A.. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost 1997; 77: 1120-6.
27 Montgomery HE, Clarkson P, Nwose OM, Mikailidis DP, Jagroop IA, Dollery C, Moult J, Benhizia F, Deanfield J, Jubb M, World M, McEwan JR, Winder A, Humphries S.. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. Arterioscler Thromb Vasc Biol 1996; 16: 386-91.
28 Almasy L, Mac Cluer JW... Association studies of vascular phenotypes. How and why?. Arterioscler Thromb Vasc Biol 2002; 22: 1055-7.
29 Palatianos GM, Bolooki H, Horowitz MD, Lowery MH, Rosenthal SP, Chandarlapaty SK, Sfakianakis GN, Kaiser GA.. Sequential internal mammary artery grafts for coronary artery bypass. Ann Thorac Surg 1993; 56: 1136-40.
30 Edwards FH, Clark RE, Schwartz M.. Impact of internal mammary conduits on operative mortality in coronary revascularization. Ann Thorac Surg 1994; 57: 27-32.
31 van Brussel BL, Ernst JM, Ernst NM, Kelder HC, Knaepen PJ, Plokker HWM, Vermeulen FE, Voors AA.. Clinical outcome in venous coronary artery bypass grafting: a 15-year follow-up study. Int J Cardiol 1997; 58: 119-26.
32 Sergeant P, Blackstone E, Meyns B.. Validation and interdependence with patient-variables of the influence of procedural variables on early and late survival after CABG. K.U. Leuven Coronary Surgery Program. Eur J Cardiothorac Surg 1997; 12: 1-19.
33 Herlitz J, Brandrup-Wognsen G, Haglid M, Hartford M, Emanuelsson H, Karlson BW, Karlsson T, Hjalmarson A.. Mortality and morbidity during a period of 2 years after coronary artery bypass surgery in patients with and without a history of hypertension. J Hypertens 1996; 14: 309-14.